Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis

Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis

Rachael L DiSantostefano,1 Hao Li,1 David Hinds,1 Dmitry V Galkin,2 David B Rubin21Worldwide Epidemiology, 2Respiratory Clinical Development, GlaxoSmithKline, Research Triangle Park, Durham, NC, USABackground: Pneumonia poses a significant risk in patients with moderate to severe chronic obstructive...

Full description

Bibliographic Details
Main Authors:	DiSantostefano RL, Li H, Hinds D, Galkin DV, Rubin DB
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-05-01
Series:	International Journal of COPD
Online Access:	http://www.dovepress.com/risk-of-pneumonia-with-inhaled-corticosteroidlong-acting-beta2-agonist-a16714

Similar Items

Estimating Inhaled Corticosteroid Exposure from Short-Acting β2-Agonist–Inhaled Corticosteroid Rescue
by: Lugogo N, et al.
Published: (2023-05-01)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
by: Yang HH, et al.
Published: (2017-08-01)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
by: Eung Gu Lee, et al.
Published: (2023-05-01)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
by: Liao PA, et al.
Published: (2023-04-01)

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids
by: Tsan-Ming Huang, et al.
Published: (2020-09-01)

Risk Factors of Local Oropharyngeal and Laryngeal Adverse Effects from Use of Single Inhaled Corticosteroids and Long-Acting Beta-Agonists
by: Nobuyuki Horita, et al.
Published: (2012-01-01)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
by: Scichilone N, et al.
Published: (2014-11-01)

Impulse Oscillometry; Therapeutic Impacts of Transdermal Long-Acting Beta-2 Agonist Patch in Elderly Asthma with Inhaled Corticosteroid Alone
by: Hiroshi Tanaka, et al.
Published: (2012-01-01)

An assessment of asthma exacerbations in pediatric patients using a long-acting B2-agonist plus inhaled corticosteroid versus an inhaled corticosteroid alone
by: Yousif S. Alakeel, et al.
Published: (2022-03-01)

Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long-acting β2-agonists/long-acting muscarinic antagonists
by: Nevin Kishore, et al.
Published: (2020-01-01)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
by: Czira A, et al.
Published: (2023-04-01)

Effects of two inhaled corticosteroid/long-acting beta-agonist combinations on small-airway dysfunction in mild asthmatics measured by impulse oscillometry
by: Diong B, et al.
Published: (2013-08-01)

Correction to: Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis
by: Céline El Baou, et al.
Published: (2017-12-01)

Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β2-agonist via dry-powder inhalers and pressurized metered-dose inhalers
by: Wittbrodt ET, et al.
Published: (2018-12-01)

Inhaled corticosteroids and the increased risk of pneumonia
by: Lucía Marzoratti, et al.
Published: (2013-08-01)

Combination long acting β agonists-inhaled corticosteroids versus dual bronchodilation: a real conflict?
by: Marco Candela
Published: (2014-10-01)

Impact of adherence to treatment with inhaled corticosteroids/long-acting β-agonists on asthma outcomes in the United States
by: Carlyne M. Averell, et al.
Published: (2022-08-01)

Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics
by: Marco Caminati, et al.
Published: (2020-04-01)

ARE INHALED LONG-ACTING BETA-AGONISTS (LABA) REALLY HARMFUL IN ADULT ASTHMATICS?
by: TNEW CL, et al.
Published: (2008-01-01)

Association between <i>ADAM33</i> Single-Nucleotide Polymorphisms and Treatment Response to Inhaled Corticosteroids and a Long-Acting Beta-Agonist in Asthma
by: Sangeetha Vishweswaraiah, et al.
Published: (2023-01-01)

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma
by: Bateman ED, et al.
Published: (2018-05-01)

Rapid corticosteroid effect on long-acting beta2-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy
by: Gabor Horvath, et al.
Published: (2008-04-01)

Inhaled Corticosteroids Is Not Associated with the Risk of Pneumonia in Asthma
by: Ye Jin Lee, et al.
Published: (2023-07-01)

Cough and asthma: the role of inhaled corticosteroids and ß2-agonists
by: Mario Cazzola, et al.
Published: (2008-02-01)

Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan
by: Hirano R, et al.
Published: (2018-10-01)

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
by: Burkes RM, et al.
Published: (2020-12-01)

Asthma and treatment with inhaled corticosteroids: associations with hospitalisations with pneumonia
by: Emil Ekbom, et al.
Published: (2019-12-01)

Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?
by: Masato Muraki, et al.
Published: (2017-01-01)

Protective effect of inhaled corticosteroid on children with asthma with Mycoplasma pneumoniae pneumonia
by: Bing Wei, et al.
Published: (2022-08-01)

Symptom-driven inhaled corticosteroid/long-acting beta-agonist therapy for adult patients with asthma who are non-adherent to daily maintenance inhalers: a study protocol for a pragmatic randomized controlled trial
by: James G. Krings, et al.
Published: (2022-12-01)

Asthma control in patients receiving inhaled corticosteroid and long-acting beta<sub>2</sub>-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation
by: Nicolini Gabriele, et al.
Published: (2011-07-01)

Comparison of efficacy between long-acting beta 2-agonists (formoterol fumarate) and leukotriene-receptor antagonists (montelukast) as add-on therapy to inhaled corticosteroids (budesonide) in moderate persistent asthma
by: Sasikala Kumaravel, et al.
Published: (2014-01-01)

Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients
by: Park HY, et al.
Published: (2015-12-01)

Inhalation devices and inhaled corticosteroids particle size influence on severe pneumonia in patients with chronic obstructive pulmonary disease: a nationwide cohort study
by: Pradeesh Sivapalan, et al.
Published: (2023-11-01)

Associated Factors of Pneumonia in Individuals with Chronic Obstructive Pulmonary Disease (COPD) Apart from the Use of Inhaled Corticosteroids
by: Rosario Lineros, et al.
Published: (2023-04-01)

The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease
by: Park JW, et al.
Published: (2023-05-01)

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years
by: C Main, et al.
Published: (2008-05-01)

Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β2-agonist dual therapy in a primary care setting in England
by: Victoria Banks, et al.
Published: (2022-10-01)

Successful treatment with inhaled corticosteroid/long-acting β2-agonist in a case of allergic bronchopulmonary mycosis caused by Schizophyllum commune
by: Muneyuki Sekiya, et al.
Published: (2023-01-01)

Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered a pressurized metered-dose inhaler
by: Cedric Van Holsbeke, et al.
Published: (2018-02-01)